The Prognostic Value of PET/CT for Tumor Progression in Patients With Metastatic Hormone-sensitive Prostate Cancer
NCT ID: NCT06915714
Last Updated: 2025-04-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
45 participants
OBSERVATIONAL
2024-06-02
2025-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Exploration of the Value of PSMA PET/CT in Dynamic Monitoring of the Efficacy of Novel Endocrine Therapy in Patients With Metastatic Hormone Sensitive Prostate Cancer
NCT06387238
68Ga-P15-041 and 68Ga-PSMA-11 PET/CT Imaging in the Same Group of Prostate Bone Metastasis
NCT05627778
Evaluation of the Metastasis and Recurrence of Prostate Cancer
NCT03507595
Monocentric Observational Study on the Diagnostic and Prognostic Role of 18F-PSMA PET (PET/CT and PET/MR) in Prostate Cancer
NCT06167629
Role of PET/CT With Fluorine-18 Tracers of Bone Metastases in Prostate Cancer
NCT01501630
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group1
PCa40%MTV-P = High, PCa40%MTV-G = Low
No interventions assigned to this group
Group2
PCa40%MTV-P = Low, PCa40%MTV-G = High
No interventions assigned to this group
Group3
PCa40%MTV-P = Low, PCa40%MTV-G = Low
No interventions assigned to this group
Group4
PCa40%MTV-P = High, PCa40%MTV-G = High
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* patients who underwent FDG and PSMA PET/CT prior to the initiation of medical treatment
Exclusion Criteria
* patients with other malignancies
* patients received hormone therapy without novel hormone therapy
* patients received chemotherapy or radiotherapy prior to or during novel hormone therapy
* absence of follow-up data at our institution
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sun Yat-sen University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Zheng fufu
Professor, Phd, Md
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Fangzheng Xiang
Role: PRINCIPAL_INVESTIGATOR
First affiliated hospital, Sun Yat-sen univeristy
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
First affiliated hospital, Sun Yat-sen univeristy
Guangzhou, Guangdong, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IIT-2025-117
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.